Future Science Group

How can we bring Parkinson’s disease into the age of personalized medicine? One such approach recently described by Alberto Espay (University of Cincinnati, OH, USA) is to subtype the disease according to the presence of certain biomarkers. This is an approach that he says could “up the ante in our ability to modify the disease”, moving us away from purely dopaminergic strategies that address only the ‘common denominator’ of the disease. We caught up with Dr Espay at the American Academy of Neurology Annual Meeting (Boston, MA, USA, 22–28 April), where he told us more about his call for a biomarker-driven approach to subtyping Parkinson’s, and how this could change the way we both research and treat the disease. You can find more podcasts, as well as the latest news and expert opinions across neuroscience and neurology, at www.neuro-central.com